Get the Stockscreener App
20.67
0.62%
-0.13
After Hours:
20.67
Dianthus Therapeutics Inc stock is traded at $20.67, with a volume of 218.54K.
It is down -0.62% in the last 24 hours and up +10.95% over the past month.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
See More
Previous Close:
$20.80
Open:
$21.5
24h Volume:
218.54K
Relative Volume:
0.72
Market Cap:
$664.75M
Revenue:
$4.12M
Net Income/Loss:
$-56.68M
P/E Ratio:
-3.7291
EPS:
-5.5429
Net Cash Flow:
$-51.44M
1W Performance:
-5.14%
1M Performance:
+10.95%
6M Performance:
-6.68%
1Y Performance:
-30.59%
1-Day Range:
$20.42
$22.17
1-Week Range:
$20.42
$23.20
52-Week Range:
$13.37
$32.27
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
20.67 | 668.93M | 4.12M | -56.68M | -51.44M | -5.5429 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-25 | Initiated | William Blair | Outperform |
| Dec-20-24 | Initiated | TD Cowen | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
How does Dianthus Therapeutics Inc. generate profit in a changing economyStock Market Ideas With Proven Results - jammulinksnews.com
Why Dianthus Therapeutics Inc. stock attracts strong analyst attentionQuarterly Investment Outlook and Key Summary - Newser
How to forecast Dianthus Therapeutics Inc. trends using time seriesFree Strong Buy With Technical Confidence - Newser
Has Dianthus Therapeutics Inc. formed a bullish divergenceSmart Chart Forecasting with AI Algorithms - Newser
Buy Signal for Dianthus Therapeutics Inc. Stock Key Technical Indicators to WatchCapital Safe Picks with Consistent Gains - Newser
Key External Factors That Drive Dianthus Therapeutics Inc. Stock Price MovementsSmart Stock Forecast Using AI Algorithms - Newser
Should I hold or sell Dianthus Therapeutics Inc. stock in 2025Entry Signal Forecasts For Consistent Profits - jammulinksnews.com
Visualizing Dianthus Therapeutics Inc. stock with heatmapsFree Smart Trend Trading with Weekly Signals - Newser
Dianthus Therapeutics Inc. Added to Custom Quant Screener TodayHigh Win Rate Trading Opportunities Detected - metal.it
How Dianthus Therapeutics Inc. stock performs during market volatilityShort-Term Price Breakout Signal Analysis - Newser
Dianthus Therapeutics’ CAPTIVATE Study: A Potential Game-Changer for CIDP Treatment - TipRanks
How volatile is Dianthus Therapeutics Inc. stock compared to the marketRapid capital growth - jammulinksnews.com
Guggenheim raises Dianthus Therapeutics stock price target ahead of trial data - Investing.com Canada
Custom watchlist performance reports with Dianthus Therapeutics Inc. Stock Market Watch with Smart Filters - Newser
What is the dividend policy of Dianthus Therapeutics Inc. stockBreakneck growth rates - jammulinksnews.com
Is Dianthus Therapeutics Inc. a growth stock or a value stockAchieve breakthrough investment performance - jammulinksnews.com
Does Dianthus Therapeutics Inc. stock perform well during market downturnsBuild wealth faster with consistent investment plans - jammulinksnews.com
Why is Dianthus Therapeutics Inc. stock attracting strong analyst attentionFree Investment Risk Control - jammulinksnews.com
How does Dianthus Therapeutics Inc. compare to its industry peersConsistent high-yield stocks - jammulinksnews.com
What makes Dianthus Therapeutics Inc. stock price move sharplyGet exclusive access to expert stock recommendations - jammulinksnews.com
Is Dianthus Therapeutics Inc. Stock a Good Fit for Conservative InvestorsFree Stock Selection - Newser
Dianthus Therapeutics Inc. Stock Analysis and ForecastAccelerated financial growth - PrintWeekIndia
What analysts say about Dianthus Therapeutics Inc. stock outlookUnmatched profit growth - jammulinksnews.com
Does Dianthus Therapeutics Inc. stock pay reliable dividendsBreakout stock performance - jammulinksnews.com
Is Dianthus Therapeutics Inc. a good long term investmentExplosive portfolio gains - jammulinksnews.com
What drives Dianthus Therapeutics Inc. stock priceHigh-profit trading signals - jammulinksnews.com
What analysts say about Dianthus Therapeutics Inc. stockGame-changing returns - jammulinksnews.com
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):